Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Prestige BioPharma Limited (950210.KS)
Singapore, SG
Established in 2015 and based in Singapore, Prestige BioPharma Limited operates as a biopharmaceutical enterprise. The company's activities encompass the research, development, and commercialization of biosimilars and novel antibody therapeutics, primarily targeting the Asia Pacific market. A significant focus for Prestige BioPharma is the creation of antibody-based treatments for critical conditions such as solid tumors, pancreatic cancer, breast cancer, gastric cancer, and arthritis. Furthermore, the firm is also advancing the development of vaccines for the COVID-19 virus.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.53% | -13.70% | -22.22% | -34.93% | -47.10% | -48.89% | -47.70% | -30.63% | -76.47% | -86.14% | -86.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+1,976.7% ★ Q4'25: +152.8% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%+167.7% ★ Q4'25: -14.8% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-9.7% Q4'25: -159.1% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%+80.6% ★ Q4'25: -242.4% (vs Q4'24)
-
ROIC Biotechnology: -16.1%+2.4% ★ Q4'25: -15.5% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q4'25: +1.7% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×4.33× ★ Q4'25: -1.84× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2022 actual |
|---|---|
| Revenue |
—
est: 166.00M (-100.0%)
|
| EBITDA |
-206.91B
est: 99.60M (-207,836.0%)
|
| EBIT |
-210.77B
est: 26.76M (-787,601.4%)
|
| Net Income |
-211.45B
|
| SGA |
101.19B
est: -8.65B (+1,269.4%)
|
| EPS |
-3,518.53
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| So-Yeon Park | Chairman & Chief Executive Officer | 759M | female |
| Jinwoo Kim | Vice Chairman of the Board & CFO | 704M | male |
| Kay Lee | Clinical Development Manager | — | female |
| Michael Ruppert | Head of Business Development | — | male |
| Neil O'Connor | CMCB Head | — | — |
| Sumiko Shiba | Secretary | — | female |
| Dong -Jo Shin | Head of Finance | — | male |
| Sumita Pradhan | R&MA Head | — | — |
| Ghislain M.C Bonamy | General Manager of Licensing | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 950210.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
